Condition: Rheumatoid Arthritis · Dermatomyositis · Systemic Lupus Erythematosus · Sponsor: The First Affiliated Hospital with Nanjing Medical University
A single arm, open-label pilot study is designed to determine the safety and effectiveness of anti-CD19/BCMA-UCAR-T cells in patients with autoimmune diseases. 36-72 patients are planned to be enrolled in the dose-escalation trial.
This description comes directly from the study's public registry record.
Wenfeng Tan · 13770769608 · Tanwenfeng2005@126.com
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital) | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07558850